Blood test may predict when colorectal cancer treatment fails

NCT ID NCT05487248

Ongoing Knowledge-focused Sponsor: Jules Bordet Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether changes in tumor DNA found in the blood (ctDNA) can predict if chemotherapy is working in people with advanced colorectal cancer that no longer responds to standard treatments. About 103 participants will give blood samples and have regular scans to track their cancer. The goal is to find the best time and cutoff for ctDNA changes to signal when the cancer is progressing, which could help doctors adjust treatment sooner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANDIDATE FOR THIRD-LINE OR SUBSEQUENT LINES OF THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANDIDATE FOR THIRD-LINE OR SUBSEQUENT LINES OF THERAPY METASTATIC COLORECTAL CANCER UNRESECTABLE LOCALLY ADVANCED COLORECTAL CANCER

Contacts and locations

Locations

CHIREC Delta

Brussels, Belgium
CHU Ambroise Pare

Mons, 7000, Belgium
CHU Poitiers

Poitiers, France
Centre Georges François Leclerc

Dijon, France
Cliniques Universitaires Saint Luc

Woluwe-Saint-Lambert, 1200, Belgium
Hopital Franco-Britannique - Fondation Cognacq-Jay

Levallois-Perret, 92300, France
Hopital St-Louis

Paris, France
Hopital privé Jean Mermoz

Lyon, France
ICANS Strasbourg

Strasbourg, France
ICO Saint-Herblain

Saint-Herblain, France
Institut Jules Bordet

Anderlecht, 1070, Belgium
UZ Antwerpen

Antwerp, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.